United States Food and Drug Administration (USFDA) has concluded surveillance inspection at Zydus group’s API Unit, located at Dabhasa in Gujarat. The inspection was conducted from April 21 to 25, 2025. The inspection concluded with 6 observations and none of them were related to Data Integrity. The company is confident to address the observations expeditiously.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
